Efficacy and safety of SARS-CoV-2 vaccines in living donor liver transplant recipients

Jadaun, Shekhar Singh; Jakkilinki, Phani Deepti; Hasnain, Ana; Tarai, Bansi Dhar; Agrawal, Dhiraj; Singh, Sukhbir; Agarwal, Shaleen; Gupta, Subhash; Saigal, Sanjiv

doi:10.1016/j.liver.2022.100116

Journal of Liver Transplantation

2022

DOI: 10.1016/j.liver.2022.100116

|View full text |Cite

Efficacy and safety of SARS-CoV-2 vaccines in living donor liver transplant recipients

Shekhar Singh Jadaun

Phani Deepti Jakkilinki

Ana Hasnain

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

T- and B-cell Immune Response to COVID Vaccination in Liver Transplant Recipients Based on Interferon-gamma Release Assay and Serum Antibody Levels

DinuAbirami,

Panneerselvam,

Mouleeswaran

et al. 2023

Gastroenterology, Hepatology and Endoscopy Practice

View full text Add to dashboard Cite

Background and Aim: This study aimed to assess T- and B-cell-mediated immune response following administration of two doses of COVID-19 vaccine in liver transplant (LT) recipients. Subjects and Methods: Twenty-eight liver transplant recipients and seven healthy volunteers without prior history of COVID-19 infection were enrolled. All individuals received two doses of COVID-19 vaccine (either Covishield or Covaxin), with the LT recipients receiving them at least 3 months after LT. The results of humoral (COVID-specific IgG) and cell-mediated immune response (interferon [INF]-gamma assay) following vaccination in the LT recipient group were compared with the control group. Results: Both LT recipients and control individuals developed COVID-specific antibodies following vaccination. The LT recipient group showed marginally higher INF-gamma levels with an average of 61.3 pg/ml compared to the control group 42.7 pg/ml (P = 0.051). There was no difference in the immunological response between patients who received the vaccination before or after 6 months posttransplant. There was no difference in response between the two vaccines. Conclusion: LT recipients mounted an immunological response comparable to the control group with both inactivated and viral vector vaccines for COVID-19, when vaccinated with an interval period of 3 months from transplant.

show abstract

T- and B-cell Immune Response to COVID Vaccination in Liver Transplant Recipients Based on Interferon-gamma Release Assay and Serum Antibody Levels

DinuAbirami,

Panneerselvam,

Mouleeswaran

et al. 2023

Gastroenterology, Hepatology and Endoscopy Practice

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy and safety of SARS-CoV-2 vaccines in living donor liver transplant recipients

Cited by 1 publication

References 5 publications

T- and B-cell Immune Response to COVID Vaccination in Liver Transplant Recipients Based on Interferon-gamma Release Assay and Serum Antibody Levels

T- and B-cell Immune Response to COVID Vaccination in Liver Transplant Recipients Based on Interferon-gamma Release Assay and Serum Antibody Levels

Contact Info

Product

Resources

About